Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities.

IF 2 Q2 UROLOGY & NEPHROLOGY

Research and Reports in Urology Pub Date : 2023-11-29 eCollection Date: 2023-01-01 DOI:10.2147/RRU.S386517

Eun-Mi Yu, Min Woo Hwang, Jeanny B Aragon-Ching

引用次数: 0

Abstract

Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progression to castration-resistant disease becomes inevitable. Aberrant pathway activations of PI3K/AKT due to PTEN loss, epithelial-mesenchymal transition pathways, homologous recombination repair, and DNA repair pathway mechanisms of resistance and cross-talk lead to opportunities for therapeutic targeting in metastatic castration-resistant prostate cancer. This review focuses on mechanisms of progression and key trials that evaluate the drugs and combinations that exploit these pathways.

查看原文本刊更多论文

局部到转移性前列腺癌转移和治疗机会的机制见解。

前列腺癌是美国男性中最常见的非皮肤癌症。多种机制参与肿瘤的发生和发展到转移。虽然雄激素剥夺疗法仍然是治疗的基石，但不可避免地会发展为去势抵抗性疾病。PTEN缺失导致的PI3K/AKT异常通路激活、上皮-间质转化通路、同源重组修复和DNA修复通路的耐药和串话机制为转移性去势抵抗性前列腺癌的靶向治疗提供了机会。这篇综述的重点是进展机制和评估利用这些途径的药物和组合的关键试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Research and Reports in Urology UROLOGY & NEPHROLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Research and Reports in Urology is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease Investigation and treatment of urological disease Pharmacology of drugs used for the treatment of urological disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered.